Paris and London (ots/PRNewswire) – In the news release, “ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe” issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read “ONGLYZA(R) [...]
Tag Archive > Diabetes Patients
ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca.com) today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg [...]
Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to [...]
Chronic Kidney Disease and Diabetes – Major Risk Factors Amongst Europe’s Population to Be Urgently Addressed
Strasbourg, France, March 10, 2010 (ots/PRNewswire) – The European Kidney Health Alliance (EKHA) and World Kidney Day (WKD) organisations today call for European Union (EU) support. Early awareness, identification and treatment of chronic kidney disease (CKD) and its associated diseases, including diabetes – the leading cause of CKD(1) – must be prioritised on the EU [...]
Gerresheimer sets up new production facility for insulin pen systems in Brazil
Düsseldorf (ots) – * Expansion of cooperation with diabetes leader Novo Nordisk * Important step in the worldwide development of medical plastic systems The Gerresheimer Group has set up a new facility for medical plastic systems in Indaiatuba (Brazil). The plant is to commence operations early in 2010. On the basis of a long-term cooperation [...]
Tolerx Completes Enrollment in DEFEND-1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
Cambridge, Massachusetts (ots/PRNewswire) – Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes. The DEFEND-1 (Durable Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) [...]
NOXXON Pharma AG announces excellent preliminary phase I trial results for Spiegelmer® NOX-E36 – good safety and pharmacodynamic profile and additional good subcutaneous bioavailability
(pressebox) Berlin, 12.10.2009, NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its antiinflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic [...]
Boehringer Ingelheim’s Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Pivotal Trials Programme for linagliptin
Ingelheim, Germany (ots/PRNewswire) – – For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III clinical trials programme consistently support the favourable efficacy and safety [...]
New Data From Boehringer Ingelheim’s Ongoing Linagliptin Trial Programme Show Promising Safety and Efficacy Results
Ingelheim, Germany (ots/PRNewswire) – – Results From Linagliptin Study in Type 2 Diabetes Patients Who Were Inadequately Controlled on Metformin Therapy Alone, Presented at Major Diabetes Meeting Study results presented for the first time in the scientific sessions of this year’s American Diabetes Association Annual Meeting (ADA) show clinically relevant and statistically significant reductions in [...]
EANS-News: CompuGROUP Holding AG / CompuGROUP and Knappschaft Bahn See launch pilot programme for integrated treatment of diabetes patients
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– companies/Integrated Treatment Koblenz (euro adhoc) – CompuGROUP Holding AG, the e-health service company with the broadest reach among service providers world-wide, is now supporting the integrated treatment of patients suffering from Type 2 diabetes mellitus through [...]
CompuGROUP and Knappschaft Bahn See launch pilot programme for integrated treatment of diabetes patients
(pressebox) Koblenz, 08.04.2009, CompuGROUP Holding AG, the e-health service company with the broadest reach among service providers world-wide, is now supporting the integrated treatment of patients suffering from Type 2 diabetes mellitus through its subsidiary GIV. Client Knappschaft Bahn See expects the programme to provide more effective patient care and reduce costs significantly. In the [...]
Tolerx Expands Phase 3 ‘DEFEND’ Trial of Otelixizumab in Europe
Cambridge, Massachusetts (ots/PRNewswire) – Tolerx, Inc., today announced that DEFEND (Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes), the Phase 3 trial of otelixizumab, an investigational novel targeted immunotherapeutic, has begun enrollment of new onset autoimmune type 1 diabetes patients in Europe. In DEFEND, preserving beta cell function subsequent to the [...]
Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
Sydney (ots/PRNewswire) – Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes and atherogenic dyslipidemia, that is, the combination of high triglyceride (2.3 mmol/L-200mg/dL or higher) and low high-density lipoprotein (HDL) cholesterol (
